BVX Insider Trading

Insider Ownership Percentage: 42.56%
Insider Buying (Last 12 Months): £1,400
Insider Selling (Last 12 Months): GBX 0

BiVictriX Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at BiVictriX Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
20222023202420250bought0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-2M-1M01M2MTotal Insider BuyingTotal Insider Selling

BiVictriX Therapeutics Share Price & Price History

Current Price: GBX 0
Price Change: +0.30 (1.20%)
As of 09/10/2024 10:18 PM ET

This chart shows the closing price history over time for BVX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
JanFebMarAprMayJunJulAugSepOctNovDec10.00Closing price on 12/20/24:

BiVictriX Therapeutics Insider Trading History

See Full Table

SEC Filings (Institutional Ownership Changes) for BiVictriX Therapeutics (LON:BVX)

30.75% of BiVictriX Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

BiVictriX Therapeutics logo
BiVictriX Therapeutics Plc, a biotechnology company, engages in the development of cancer therapies in the United Kingdom. The company develops Bi-Cygni therapeutics, which are selective for cancer types. Its lead program is BVX001, focuses on acute myeloid leukaemia, as well as develops BVX002 and BVX003 for various blood cancers and solid tumours. BiVictriX Therapeutics Plc was founded in 2016 and is headquartered in Macclesfield, the United Kingdom.
Read More on BiVictriX Therapeutics

Today's Range

Now: N/A

50 Day Range

MA: GBX 10
Low: 10
High: 10

52 Week Range

Now: N/A

Volume

1,538,020 shs

Average Volume

108,326 shs

Market Capitalization

£8.25 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of BiVictriX Therapeutics?

BiVictriX Therapeutics' top insider shareholders include:
  1. Robert Edward Hawkins (Insider)
Learn More about top insider investors at BiVictriX Therapeutics.